New drug delivery system could reduce daily diabetes shots to just three a year
Dietary management drugs have transformed Type 2 diabetes care, but daily injection routines are challenging for some patients
Andrea Ivana d'Aquino / Stanford University
These drugs all work by mimicking the hormone glucagon-like peptide 1 (GLP-1). But, as good as they are at helping people manage their diets and their weight, the typical daily or weekly injections are a burden for many patients.
“Adherence is one of the biggest challenges in Type 2 diabetes management,” said Eric Appel, associate professor of materials science and engineering at Stanford and principal investigator on the new hydrogel that allows the slow release of the diet control drugs over many months. “Needing only three shots a year would make it much easier for people with diabetes or obesity to stick with their drug regimens.”
Half a billion people worldwide suffer from Type 2 diabetes, including 130 million in America alone. Treatment is estimated to cost the United States upward of $400 billion each year. Introduced only recently, the GLP-1 drugs have been described as “miracle drugs” with few side effects and profound control of energy intake by helping patients feel more satiated and less hungry, and by targeting other reward-related dietary effects.
Novel nanocomposite hydrogels
The secret of the hydrogel is in the unique physical characteristics of the nanoparticles at its heart. Hydrogels are not new – many people today wear contact lenses made of hydrogels, for instance – but these are engineered to resist tearing and to hold their shape. Appel’s hydrogel is instead engineered with polymers and nanoparticles that are weakly bound to one another, so as to hold together as a gel yet dissipate slowly over time. The hydrogel is formed from a mesh of polymer chains and nanoparticles that hold the drug molecules until the mesh dissolves away, releasing the drugs.
“Our hydrogel melts away over many months like a sugar cube dissolving in water, molecule by molecule,” Appel explained. “I often refer to the mesh being held together by a sort of molecular Velcro that sticks together quite well, but then can be easily pulled apart.”
The new hydrogel, technically known as a polymer-nanoparticle (PNP) hydrogel, has a Goldilocks “just right” quality of fluidlike flow that can be easily injected using off-the-shelf needles, yet a gel-like stability durable enough in the body to last the full four-month period. Molecules of the GLP-1 drugs are formulated into the hydrogel and are similarly doled out over time as the hydrogel slowly melts away.
The physician injects a small dollop of gel, known as a “depot,” of the drug-laden hydrogel under the skin in a convenient location such as under the arm. The key for the engineer is to design the hydrogel in such a way as to make this depot small enough to be comfortable and inconspicuous to the patient, yet large enough and durable enough to last the full four months. Appel believes his team has achieved that measure of control.
“We chose four months to match the cadence that people actually meet with their physician or endocrinologist and why we were so specific with the release period,” Appel said.
So far, the team has tested the new drug delivery system in laboratory rats with high success. In rats, a single injection of this hydrogel-based therapy improves management of blood glucose and weight compared to daily injections of a leading commercial drug, Appel noted.
While this particular hydrogel was engineered specifically for the GLP-1 four-month checkup regimen, Appel said that the team has successfully tuned the release timeframes to anywhere from days to upward of six months. He adds that such systems have been used with other proteins, vaccines, and even therapeutic cells, and there is evidence that GLP-1 drugs can also reduce risk of cardiovascular disease.
All these signs point to the promising possibility that this drug delivery system can be applied to other drugs and other conditions.
“There’s even been really promising results with children with Type 1 diabetes,” Appel said of the promise ahead.
Next up will be tests in pigs, whose skin and endocrine systems are most similar to those in humans. If those trials go according to plan, Appel could see human clinical trials within a year and a half to two years.
“At the very least, we have laid a pathway for the prolonged release of therapeutic GLP-1–based anti-diabetic and anti-obesity treatments that could have beneficial impact on Type 2 diabetes management and, perhaps, other conditions as well,” Appel said.
Other news from the department science
A new approach to recording cellular activities
Potential for accelerating research: A novel chemical labeling method allows transient events in cells to be recorded for later analysis
Scientists deliver portable total chemical analysis without pumps and tubes
The portability of the new device enables bedside, quantitative clinical analysis or environmental analysis in the field
99 million people included in largest global COVID-19 vaccine safety study
Global Vaccine Data Network utilises vast data sets to detect potential vaccine safety signals
Graphene research: numerous products, no acute dangers
Successful completion of the EU Graphene Flagship
Powering Nitrogenases: New ways for sustainable fertiliser production
New targets for improving biocatalysts
Using metabolomics for assessing safety of chemicals may reduce the use of lab rats
"We hope that learnings from this research will be included in new guidance for the chemical industry to allow commercial laboratories to provide these services widely"
Revolutionary cell therapy: rebooting the immune system stops autoimmune diseases
Single infusion of CAR-T cells replaces immunosuppressive drugs
Cracking the Code of Neurodegeneration: New Model Identifies Potential Therapeutic Target
Novel neural cell culture model developed
IQ does not remain the same throughout life
A meta-study shows that an intelligence quotient measured once is not necessarily meaningful later on
New mechanism for regulating cell division in the bacterial pathogen Klebsiella uncovered
Small ribonucleic acid with a big impact
More brain than trait: Decoding the neural pathways of curiosity
Discovery sheds new light on the biological basis of human curiosity and could have far-reaching implications for the understanding and treatment of diseases
What Our Genetic Information Tells Us About Type 2 Diabetes Risk and Complications
Largest Study on Genetic Risk for Diabetes Now Published
Study Proposes Framework to Standardize Biomarkers of Aging and Accelerate Clinical Use
Improving the life expectancy and health of the population
Researchers succeeded in biomanufacturing using chemically synthesized sugar for the first time in the world
Biomanufacturing using chemically synthesized sugars enables sustainable supply of sugar without competing with food
Most read news
The secret of whales: How giant whales defy cancer
Study of gigantism in whales provides clues to genomic mechanism involved in tumor suppression
mRNA therapeutic successfully combats ovarian cancer
The mRNA therapeutic successfully combated cancerous cells and tumors in vitro as well as metastases in mice
Microbe of the Year 2023: Bacillus subtilis – for health and technology
Already, Bacillus subtilis is indispensable in many industries, and many more innovations are expected
A standard blood test can predict a heart attack
Using the results of a standard blood test and an online tool, you can find out if you are at increased risk of having a heart attack within six months
Making Ends Meet: Researchers Find That a Protein Superglue is Crucial for DNA Damage Repair
New Understanding for Cancer Treatments
Learning from Nature: How a fungus makes a hard job easier
Researchers analyze a fungal biosynthetic pathway and discover a capable enzyme
Innovative microscopy technique reveals secrets of lipid synthesis inside cells
Two-color infrared photothermal microscopy (2C-IPM) opens new avenues for long-term study of lipid metabolism in living cells
Artificial cartilage with the help of 3D printing
New approach to producing artificial tissue works with cells in microstructures from the 3D printer
Destroying Tumor Cells with Calcium
Activating calcium channels leads to a deadly influx of calcium ions into tumor cells
Pregnant women should avoid ultraprocessed, fast foods
Curiously, it’s not the food that the study targets but what touches the food before you eat it
Swiss longevity biotech receives support from L'Oréal and Nestlé
Timeline Secures Pivotal Financing Round
More news from our other portals
Planned EU legislation on packaging threatens popular seasonal confectionery
Federal Association of the German Confectionery Industry fears the end of chocolate Easter bunnies & Co.
Mystery of Novel Clove-Like Off-Flavor in Orange Juice Solved
Tracking down off-flavours using techniques such as gas chromatography-olfactometry and aroma extract dilution analysis
Green steel from toxic red mud
An economical process with green hydrogen can be used to extract CO2-free iron from the red mud generated in aluminium production
BASF and Envision Energy enter a collaboration to drive sustainable energy solutions
Collaboration to accelerate conversion of green hydrogen and CO2 to e-methanol
Eckes-Granini further expands important out-of-home business segment
Market share gains and double-digit sales growth in 2023
Chemists are on the hunt for the other 99 percent
New mass spectrometry combo offers promise for tapping nature’s unknown chemical universe
GPT-3 for chemical research
Researchers develop fast and user-friendly language model for chemical tasks
Microgreens made to order
Italian scientists have tailored iodine and potassium content of radishes, peas, rocket and chard
Revolutionizing batteries: Coffee grounds power high-performance sodium-ion anodes
Using coffee waste as a precursor material for hard carbon synthesis
Greetings from the island of enhanced stability: The quest for the limit of the periodic table
A fresh view on new superheavy elements
Detect 'forever chemicals' in under 3 minutes
New lab-based method to detect traces of PFAS from food packaging material, water and soil samples
Celebrate carnival and do good with gin: Lost Sisters Limited Dry Gin
Lost Sisters Edition aims to generate 11,110 euros in donations with gin de cologne during the carnival season
Ferrero Group continues its growth trajectory
The Group expanded its presence in North America with the strategic acquisition of ice cream maker Wells Enterprises Inc.